This casebook collects 64 case studies, each of which raises an important and difficult ethical issue connected with planning, reviewing, or conducting health-related research. The book’s purpose is to contribute to thoughtful analysis of these issues by researchers and members of research ethics ...committees (RECs, known in some places as ethical review committees or institutional review boards), particularly those involved with studies that are conducted or sponsored internationally.
more
Nature | Vol 600 | 2 December 2021 |
Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.
2018
9th Edition
Offering information on HIV/AIDS treatment, prevention, and research
Orientations provisoires 19 juillet 2021
AIDSTAR-One | CASE STUDY SERIES November 2012
This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implement...ing TB care and prevention and R&D into new tools. This Global Plan has already informed the Global Fund Investment Case and the 2022 G20 deliberations on TB. It will serve as a key document for inspiring and aligning global advocacy efforts, such as for the upcoming UNHLM on TB in 2023.
more
Lancet 2013; 381: 1405–16
Series: Childhood Pneumonia and Diarrhoea no.1
Towards a world free of tuberculosis
Each year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to
prevent, diagnose, control or cure neglected diseases in low- and middle-income countries, making it the go...ld standard in tracking and reporting global funding for neglected disease R&D. This year’s report, the sixteenth overall, focuses on investments made in participants’ 2022 financial year (‘FY2022’) and, for the first time, adds comprehensive coverage of the product pipeline in each disease area.
more
Revised and expanded version of the Guidelines
Research Article
BMC Infectious Diseases 2014, 14:91/1471-2334/14/91